Stock Analysis of Galecto Inc (GLTO) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code GLTO
Close 0.608
Change -0.0020 / 0.328 %
Volume 71933.00
Vol Change -69415.00 / 49.11 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Very Low Growth Stock
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Galecto Inc
PE (TTM)

-129.04

Very Poor
Price / Book

105.55

Very Poor
Price / Sales

3370.35

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

16484.52 K

Enterprise Value

-4797.48 K

ROA (TTM)

-64.28

Very Poor
ROE (TTM)

-81.80

Very Poor
Net Margin (TTM)

-2611.81

Very Poor
Revenue

%

0
Net Profit

25.45 %

-45943.00 K
Debt to Equity

0.0057

Excellent
Altman Z Score

-10.70

Very Poor
Quick Ratio

6.31

Excellent
Cash Ratio

5.69

Very Good


Highs/Lows of Galecto Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.6299 3.48 % 0.513 % 0.62750.628-May-2431-May-24
Two Week0.6211 2.11 % 0.486 % 0.6450.622-May-2431-May-24
One Month0.6755 9.99 % 4.80 % 0.740.603-May-2431-May-24
Three Month0.7202 15.58 % 3.56 % 0.940.608-Mar-2431-May-24
Six Months0.63 3.49 % 15.54 % 0.940.5608-Mar-2420-Dec-23
One year2.18 72.11 % 26.26 % 3.70.526-Jul-2301-Nov-23
Two year1.31 53.59 % 27.72 % 3.70.526-Jul-2301-Nov-23


Technical View of Galecto Inc
RSI

36.20

Neutral
MACD

-0.0243

Bearish
ADX

23.55

Bearish
Super Trend

0.700

Mild Bearish
Williams %R

-92.00

Mild Bullish
CCI

-79.55

Neutral


EMA 5

0.613

Mild Bearish
EMA 15

0.633

Strong Bearish
EMA 50

0.674

Mild Bearish
EMA 100

0.712

Strong Bearish
SMA 100

0.697

Mild Bearish
SMA 200

0.658

Mild Bearish
SMA 5 / 20

0.615 / 0.651

Mild Bearish
SMA 15 / 50

0.633 / 0.690

Strong Bearish
SMA 50 / 200

0.690 / 0.658

Bullish




Charts of Galecto Inc


Returns of Galecto Inc with Peers
Period / StockGLTOMHUAPMCBATHE
1 Week-3.48%0.769%-8.41%-6.50%
1 Mth-9.99%-4.95%-7.55%-10.74%
3 Mth-15.58%-7.08%-6.67%0%
6mth-3.49%-64.02%-13.27%3.31%
1 Year-72.11%-76.27%-37.78%-35.74%
2 Year-53.59%-88.61%-14.78%-72.09%
5 Years---96.57%-85.73%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Galecto Inc with Peers
Ratio / StockGLTOMHUAPMCBATHE
PE-129.041.68-1.990
P/B105.550.1100.362144.37
ROA-64.285.61-15.090
ROE-81.806.59-22.070
Debt To Equity0.00570.05000.0047
Revenue0
% 		97098.91 K
6.05 % 		0
% 		2608.45 K
66.75 %
Net Income-45943.00 K
25.45 % 		11625.42 K
86.22 % 		-4315.99 K
1.81 % 		-13806.51 K
7.47 %


Technicals of Galecto Inc with Peers
Technical / StockGLTOMHUAPMCBATHE-
ADX23.5515.1817.9219.16
CMF-0.1400.209-0.0600.0380
MFI27.3032.9429.8945.53
RSI36.2042.8436.3641.48
MACD Abv SignalFalseFalseFalseFalse
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Galecto Inc

Address : Ole Maaloes Vej 3, Copenhagen, Denmark, 2200
Tel : 45 70 70 52 10
URL : https://galecto.com
Code : GLTO, ISIN : US36322Q1076, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 29_Oct_2020
Employee Count : 13

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.


Note : All Data Generated at the End of Trading Hours (EOD Data)